Xitrical

Xitrical is a San Diego-based biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for cancer. The company leverages a proprietary drug discovery platform designed to target "undruggable" proteins and pathways essential for tumor growth and survival. By combining advanced chemical biology with innovative screening techniques, Xitrical aims to develop highly potent and selective therapies, including targeted protein degraders. The company is currently in the pre-clinical stage, advancing its internal pipeline toward IND-enabling studies to address significant unmet needs in oncology. Xitrical's approach focuses on novel mechanisms of action to provide transformative treatment options for patients with limited therapeutic alternatives.